To inform about the FDA approval of floretyrosine F 18 (Pixclara) for PET imaging in glioma.
Approach:
FDA Approval: The FDA approved floretyrosine F 18 for differentiating recurrent or progressive glioma from treatment-related changes.
Clinical Use: Floretyrosine F 18 is the first FDA-approved FET-PET imaging drug for glioma, recommended in international clinical practice guidelines.
Administration and Mechanism: Floretyrosine F 18 is administered intravenously and targets L-type amino acid transporters, incorporating fluorine-18 for PET detection.
Safety Evaluation: Safety was evaluated in 382 patients, with minimal adverse effects reported.
Key Findings:
Floretyrosine F 18 is approved for use in adults and pediatric patients aged 1 month or older.
Approximately 24,000 new glioma cases are diagnosed annually in the US.
Interpretation:
PET results should be interpreted with caution, as they cannot definitively exclude or establish recurrent glioma.
Limitations:
Image misinterpretation may occur, leading to false-positive or false-negative results.
Conclusion:
FDA approval of Pixclara will enhance access to FET-PET imaging in the US.
